EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers

Natcha Watanapokasin iD, Worawat Rawangban, Napadon Tangjaturonrasme iD

The Laryngoscope · 2024

DOI: 10.1002/lary.31544 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Laryngoscope, 2024. Verfasst von Natcha Watanapokasin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Xerostomia, Pilocarpine, Head and Neck Neoplasms, Cross-Over Studies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Faculty of Medicine, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to evaluate the efficacy of as‐needed pilocarpine for the management of radiation‐induced xerostomia. Additionally, the study sought to assess the side effects associated with an as‐needed regimen.

Methods

A randomized, double‐blinded, placebo‐controlled crossover study was conducted on patients who had undergone radiation therapy for head and neck cancers and developed xerostomia. Participants took pilocarpine or placebo as needed for symptom relief at 2 weeks per treatment, which included a one‐week washout period. The primary outcome measure was the severity of dry mouth symptoms, quantified using the Xerostomia Inventory (XI). The primary outcome was the change in the XI score.

Results

Among the 20 participants who completed the crossover study, there was a significant reduction in XI scores during the treatment phase with pilocarpine compared to the scores during the placebo phase. The mean difference in XI scores was −18.05 (95% CI: −17.17, −6.13, p < 0.001), with a−49.77 ± 3.22% change ( p < 0.001). Only one participant withdrew due to pilocarpine side effects.

Conclusion

As‐needed pilocarpine administration is effective in relieving symptoms of radiation‐induced xerostomia, with fewer side effects and reduced treatment costs compared to fixed‐dose regimens. This study guides the potential shift toward flexible dosing strategies in clinical practice, promoting enhanced patient‐centered, tailored care and adherence. Level of Evidence 2. According to the Oxford Center for Evidence‐Based Medicine 2011 level of evidence guidelines Laryngoscope , 134:4542–4548, 2024

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

XerostomiaPilocarpineHead and Neck NeoplasmsCross-Over StudiesRadiation InjuriesHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedMuscarinic AgonistsTreatment OutcomeAdult

Stichwörter der Autor:innen

as‐needed regimenhead and neck cancerpilocarpineradiation therapyxerostomia

Substanzen

PilocarpineMuscarinic Agonists

Autor:innen und Institutionen

  • Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Natcha Watanapokasin, Napadon Tangjaturonrasme

Förderung

  • Faculty of Medicine, Chulalongkorn University

Zitieren

APA

Watanapokasin, N., Rawangban, W., & Tangjaturonrasme, N. (2024). As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers. The Laryngoscope. https://doi.org/10.1002/lary.31544

Vancouver

Watanapokasin N, Rawangban W, Tangjaturonrasme N. As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers. The Laryngoscope. 2024. doi:10.1002/lary.31544

BibTeX
@article{Watanapokasin2024,
  author = {Watanapokasin, Natcha and Rawangban, Worawat and Tangjaturonrasme, Napadon},
  title = {As‐Needed Pilocarpine for Radiation‐Induced Xerostomia in Head and Neck Cancers},
  journal = {The Laryngoscope},
  year = {2024},
  doi = {10.1002/lary.31544}
}
Kostenlos starten →